Investigating the Effect of the Non-nutritive Sweetener Sucralose in Inflammatory Bowel Disease
NCT07852273
This study is recruiting at 3 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study will focus on the commonly used non-nutritive sweetener (NNS) sucralose (2 sachets/day resulting in daily dose: sucralose 2.5mg/kg) and its role in changing the gut microbiota in humans with Inflammatory Bowel Disease (IBD), compared to healthy non-IBD individuals. We will focus on studying IBD patients affected with Crohn's Disease (CD) as a proof of principle that could be tested later in other IBD subtypes (ulcerative colitis or others specific surgical conditions).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Inflamatory Bowel Disease
- Crohn Disease (CD)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Case Western Reserve University
- Last updated on ClinicalTrials.gov
- October 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Ohio · 3
- UH Minoff Health Center · Chagrin Falls, OH
- University Hospitals Cleveland Medical Center · Cleveland, OH
- UH Westlake Health Center · Westlake, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.